In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Thomas LundMichael Tveden GundesenAnnette Juul VangstedCarsten HellebergEinar HaukåsTrine SilkjærJon Thor AsmussenElena Manuela TeodorescuBo Amdi JensenTobias Schmidt SlørdahlHareth NahiAnders WaageNiels AbildgaardSchjesvold Fredriknull nullPublished in: Blood cancer journal (2024)